Blocking ubiquitination of hnRNPA1 maintains the self-renewal of breast cancer stem cells via mutually exclusive splicing of PKM pre-mRNA.
Saved in:
| Title: | Blocking ubiquitination of hnRNPA1 maintains the self-renewal of breast cancer stem cells via mutually exclusive splicing of PKM pre-mRNA. |
|---|---|
| Authors: | Lv X; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.; Pharmaceutical Experiment Teaching Center, School of Pharmacy, China Medical University, Shenyang, China., Han L; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.; Liaoning Key Laboratory of molecular targeted antitumor drug development and evaluation, Shenyang, China., Tong WW; Department of Laboratory Medicine, Shengjing Hospital of China Medical University, Shenyang, China., Sun X; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.; Liaoning Key Laboratory of molecular targeted antitumor drug development and evaluation, Shenyang, China., Xu S; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.; Liaoning Key Laboratory of molecular targeted antitumor drug development and evaluation, Shenyang, China., Yan Y; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.; Liaoning Key Laboratory of molecular targeted antitumor drug development and evaluation, Shenyang, China., Zhou S; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.; Liaoning Key Laboratory of molecular targeted antitumor drug development and evaluation, Shenyang, China., Zhang Y; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.; Liaoning Key Laboratory of molecular targeted antitumor drug development and evaluation, Shenyang, China., Zhang D; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.; Liaoning Key Laboratory of molecular targeted antitumor drug development and evaluation, Shenyang, China., Wang J; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.; Liaoning Key Laboratory of molecular targeted antitumor drug development and evaluation, Shenyang, China., Liu J; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.; Liaoning Key Laboratory of molecular targeted antitumor drug development and evaluation, Shenyang, China., Zhao H; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.; Liaoning Key Laboratory of molecular targeted antitumor drug development and evaluation, Shenyang, China., Yao W; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.; Liaoning Key Laboratory of molecular targeted antitumor drug development and evaluation, Shenyang, China., Xiao R; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.; Liaoning Key Laboratory of molecular targeted antitumor drug development and evaluation, Shenyang, China., Wang Q; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.; Liaoning Key Laboratory of molecular targeted antitumor drug development and evaluation, Shenyang, China., Xu J; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.; Liaoning Key Laboratory of molecular targeted antitumor drug development and evaluation, Shenyang, China., Gong L; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.; Liaoning Key Laboratory of molecular targeted antitumor drug development and evaluation, Shenyang, China., Wei M; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China. mjwei@cmu.eud.cn.; Liaoning Key Laboratory of molecular targeted antitumor drug development and evaluation, Shenyang, China. mjwei@cmu.eud.cn.; Liaoning Medical Diagnosis and Treatment Center, Shenyang, China. mjwei@cmu.eud.cn., Chen B; Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, China. bochen@cmu.edu.cn., He M; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China. hemiao_cmu@126.com.; Liaoning Key Laboratory of molecular targeted antitumor drug development and evaluation, Shenyang, China. hemiao_cmu@126.com. |
| Source: | Oncogene [Oncogene] 2026 Jun; Vol. 45 (20), pp. 1914-1929. Date of Electronic Publication: 2026 Apr 14. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5594 (Electronic) Linking ISSN: 09509232 NLM ISO Abbreviation: Oncogene Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
